絞り込み

16399

広告

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

著者 Moshfeghi AA , Rosenfeld PJ , Puliafito CA , Michels S , Marcus EN , Lenchus JD , Venkatraman AS
Ophthalmology.2006 Nov ; 113(11):2002.e1-12.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.

スターを付ける スターを付ける     (1,078view , 0users)

Full Text Sources

Medical

Other Literature Sources

To evaluate the safety, efficacy, and durability of bevacizumab for the treatment of subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD).
PMID: 17027972 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード